Lipidor AB (publ) has signed an agreement with Cliantha Research to conduct a phase III study with the drug candidate AKP02G2, for the treatment of psoriasis. The study is expected to begin recruitment of patients in the first half of 2024 and Lipidor hopes to be able to present study results already in December of the same year. During the spring and summer, AKP02G2, the modified formulation of AKP02, underwent careful internal and external evaluation.

The results have been very promising, and the properties of the new formulation mean that it can be expected to provide a stronger therapeutic effect compared to its predecessor AKP02. At the beginning of the summer, the Swedish Medicines Agency made the assessment that AKP02G2 can be used directly in a new clinical phase III study, after which the planning work for such a study was intensified. The design of the study is based on experiences from the previous phase III study for AKP02, and Lipidor has chosen to collaborate with Cliantha Research, which is a reputable CRO (Clinical Research Organization) with solid experience in dermatological research.

In addition to selecting a CRO, the planning work for the clinical study has also included a process to select and start work with a manufacturer of clinical trial material (CMO). For CMO, Lipidor has chosen Med files Oy in Finland, which has initiated preparations for production of the clinical trial material so that this can be available by the start of the study. A prerequisite for the phase III study to be carried out according to plan is that Lipidor is to have new funding in place.